6-substituted isoquinolines and isoquinolinones

1. A compound of the formula (I)

wherein

R 1 is H, OH or NH 2 ;

R 3 is H, halogen, CN, (C 1 -C 6 )alkyl, OH, NH 2 , or NHR′;

R 4 is H, halogen, hydroxy, CN, (C 1 -C 6 )alkyl, R′, or (C 1 -C 6 )alkylene-R′;

R 5 is H, halogen, CN, (C 1 -C 6 )alkyl, or R′;

R 7 is H, halogen, CN, (C 1 -C 6 )alkyl, O—(C 1 -C 6 )alkyl, R′, or SO 2 —NH 2 ;

R 8 is H, halogen or (C 1 -C 6 )alkyl;

R 9 is

R′,

OH,

halogen,

(C 1 -C 6 )alkyl,

O—(C 1 -C 6 )alkyl,

(C 1 -C 6 )alkylene-R′,

(C 2 -C 6 )alkenyl,

(C 2 -C 6 )alkynyl,

(C 1 -C 6 )alkylene-O—R′,

(C 1 -C 6 )alkylene-CH[R′] 2 ,

(C 1 -C 6 )alkylene-C(O)—R′,

(C 1 -C 6 )alkylene-C(O)NH 2 ,

(C 1 -C 6 )alkylene-C(O)NH—R′,

(C 1 -C 6 )alkylene-C(O)NH—(C 1 -C 6 )alkyl,

(C 1 -C 6 )alkylene-C(O)N[(C 1 -C 6 )alkyl] 2 ,

(C 1 -C 6 )alkylene-C(O)N[R′] 2 ;

(C 1 -C 6 )alkylene-C(O)O—(C 1 -C 6 )alkyl,

COOH,

C(O)O—(C 1 -C 6 )alkyl,

C(O)OR′

C(O)(C 1 -C 6 )alkyl,

C(O)R′,

C(O)NH 2 ,

C(O)—NH—(C 2 -C 6 )alkenyl,

C(O)—NH—(C 2 -C 6 )alkynyl,

C(O)NH—(C 1 -C 6 )alkyl,

C(O)NHR′,

C(O)—NH(C 1 -C 6 )alkylene-R′,

C(O)N[(C 1 -C 6 )alkyl]R′

C(O)N[(C 1 -C 6 )alkyl] 2 ,

C(O)—(C 1 -C 6 )alkylene-R′, or

C(O)O(C 1 -C 6 )alkylene-R′,

R 6 is absent;

or is one (C 1 -C 4 )alkylene bound to the cycloalkyl ring, in which the (C 1 -C 4 )alkylene forms a second bond to a different carbon atom of the cycloalkyl ring to form a bicyclic ring system, wherein in the bicyclic ring system optionally one or two carbon atoms are replaced by a group independently selected from O, N—R 15 , S, SO or SO 2 ;

or, if m and s are 2, m is 3 and s is 1, or m is 4 and s is 0,

R 6 is CH 2 —CH—(CH 2 ) 2 which is bound with one CH 2 to the cycloalkyl ring and the two other CH 2 are bound to different carbon atoms of the cycloalkyl ring;

and, if m is 3 and s is 3,

R 6 are two methylene groups bound to different carbon atoms of the cycloalkyl ring, wherein the methylene groups or the CH 2 —CH—(CH 2 ) 2 group are bound to carbon atoms of the cycloalkyl ring such that they form an adamantane system of the formula

wherein L can be bound to any secondary or tertiary carbon atom and

wherein the bicyclic ring system or adamantane system is unsubstituted or optionally substituted by R 9 ;

R 10 is

(C 1 -C 6 )alkyl,

(C 1 -C 8 )heteroalkyl,

(C 3 -C 8 )cycloalkyl,

(C 3 -C 8 )heterocycloalkyl,

(C 1 -C 6 )alkylene-(C 3 -C 8 )cycloalkyl,

(C 1 -C 6 )alkylene-(C 6 -C 10 )aryl,

(C 1 -C 6 )alkylene-(C 5 -C 10 )heteroaryl,

(C 1 -C 6 )alkylene-(C 3 -C 8 )heterocycloalkyl,

C(O)NH—(C 1 -C 6 )alkyl,

C(O)N[(C 1 -C 6 )alkyl] 2

C(O)NH—R′,

C(O)N—((C 1 -C 6 )alkyl)-R′, or

C(O)NH—(C 1 -C 6 )alkylene-R′;

R 11 is

H,

(C 1 -C 6 )alkyl,

(C 1 -C 6 )alkylene-R′

R′,

or R 11 and R 12 together with carbon atom to which they are attached form a (C 3 -C 8 )cycloalkyl or a (C 3 -C 8 )-heterocycloalkyl ring;

R 12 is

(C 1 -C 6 )alkyl,

(C 3 -C 8 )cycloalkyl,

(C 5 -C 10 )heteroaryl,

(C 3 -C 8 )heterocycloalkyl, or

(C 6 -C 10 )aryl;

or R 12 is H, provided that r=2 and the other R 12 is not H;

or R 11 and R 12 together with carbon atom to which they are attached form a (C 3 -C 8 )cycloalkyl or a (C 3 -C 8 )-heterocycloalkyl ring;

R 13 and R 14 are independently of each other

H,

R′,

(C 1 -C 6 )alkyl,

(C 1 -C 6 )alkylene-R′,

(C 1 -C 6 )alkylene-O—(C 1 -C 6 )alkyl,

(C 1 -C 6 )alkylene-O—R′,

(C 1 -C 6 )alkylene-CH[R′] 2 ,

(C 1 -C 6 )alkylene-C(O)—R′,

(C 1 -C 6 )alkylene-C(O)NH 2 ,

(C 1 -C 6 )alkylene-C(O)NH—R′,

(C 1 -C 6 )alkylene-C(O)NH—(C 1 -C 6 )alkyl,

(C 1 -C 6 )alkylene-C(O)N[(C 1 -C 6 )alkyl] 2 ,

(C 1 -C 6 )alkylene-C(O)N[R′] 2 ,

(C 1 -C 6 )alkylene-C(O)O—(C 1 -C 6 )alkyl,

C(O)O—(C 1 -C 6 )alkyl,

C(O)OR′,

C(O)(C 1 -C 6 )alkyl,

C(O)R′,

C(O)NH—(C 1 -C 6 )alkyl,

C(O)NHR′,

C(O)N[(C 1 -C 6 )alkyl]R′

C(O)N[(C 1 -C 6 )alkyl] 2 ,

C(O)—(C 1 -C 6 )alkylene-R′,

C(O)O(C 1 -C 6 )alkylene-R′, or

R 13 and R 14 , together with the N-atom to which they are attached, form a (C 3 -C 8 ) heterocycloalkyl;

R 15 is H or (C 1 -C 6 )alkyl;

n is 0, 1, 2, 3 or 4;

m is 1, 2, 3 or 4;

s is 0, 1, 2, or 3;

r is 1 or 2;

L is O(CH 2 )p, S(CH 2 )p, S(O)(CH 2 )p, SO 2 (CH 2 )p, NH(CH 2 )p, N(C 1 -C 6 )alkyl-(CH 2 )p, N(C 3 -C 6 )cycloalkyl-(CH 2 )p; or N[(C 1 -C 3 )alkylene-R′]—(CH 2 )p;

p is 0, 1, 2, 3 or 4;

R′ is

(C 3 -C 8 )cycloalkyl,

(C 5 -C 10 )heteroaryl,

(C 3 -C 8 )heterocycloalkyl,

(C 6 -C 10 )aryl;

wherein in residues R 3 to R 15 alkyl or alkylene is unsubstituted or optionally substituted one or more times by OH, OCH 3 , C(O)OH, C(O)OCH 3 , NH 2 , NHCH 3 , N(CH 3 ) 2 , C(O)NH 2 , C(O)NHCH 3 or C(O)N(CH 3 ) 2 ;

wherein in residues R 3 to R 15 cycloalkyl or heterocycloalkyl is unsubstituted or optionally substituted one or more times by (C 1 -C 6 )alkyl, halogen, OH, OCH 3 , C(O)OH, C(O)OCH 3 , NH 2 , NHCH 3 , N(CH 3 ) 2 , C(O)NH 2 , C(O)NHCH 3 or C(O)N(CH 3 ) 2 ;

wherein in residues R 3 to R 15 alkyl or alkylene is unsubstituted or optionally substituted one or more times by halogen;

wherein in residues R 3 to R 15 (C 6 -C 10 )aryl and (C 5 -C 10 )heteroaryl are unsubstituted or optionally substituted one or more times by a group independently selected from halogen, OH, NO 2 , N 3 , CN, C(O)—(C 1 -C 6 )alkyl, C(O)—(C 6 -C 10 )aryl, C(O)OH, C(O)O(C 1 -C 6 )alkyl, C(O)NH 2 , C(O)NH(C 1 -C 6 )alkyl, C(O)N[(C 1 -C 6 )alkyl] 2 , (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkylene-NH(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylene-N[(C 1 -C 6 )alkyl] 2 , (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, O—(C 1 -C 6 )alkyl, O—C(O)—(C 1 -C 6 )alkyl, PO 3 H 2 , SO 3 H, SO 2 —NH 2 , SO 2 NH(C 1 -C 6 )alkyl, SO 2 N[(C 1 -C 6 )alkyl] 2 , S—(C 1 -C 6 )alkyl, SO—(C 1 -C 6 )alkyl, SO 2 —(C 1 -C 6 )alkyl, SO 2 —N—CH—N[(C 1 -C 6 )alkyl] 2 , SF 5 , C(NH)(NH 2 ), NH 2 , NH—(C 1 -C 6 )alkyl, N[(C 1 -C 6 )alkyl] 2 , NH—C(O)—(C 1 -C 6 )alkyl, NH—C(O)O—(C 1 -C 6 )alkyl, NH—SO 2 —(C 1 -C 6 )alkyl, NH—SO 2 —(C 6 -C 10 )aryl, NH—SO 2 —(C 5 -C 10 )heteroaryl, NH—SO 2 —(C 3 -C 8 )heterocycloalkyl, N(C 1 -C 6 )alkyl-C(O)—(C 1 -C 6 )alkyl, N(C 1 -C 6 )alkyl-C(O)O—(C 1 -C 6 )alkyl, N(C 1 -C 6 )alkyl-C(O)—NH—(C 1 -C 6 )alkyl], (C 6 -C 10 )aryl, (C 1 -C 6 )alkylene-(C 6 -C 10 )aryl, O—(C 6 -C 10 )aryl, O—(C 1 -C 6 )alkylene-(C 6 -C 10 )aryl, (C 5 -C 10 )heteroaryl, (C 3 -C 8 )heterocycloalkyl, (C 1 -C 6 )alkylene-(C 5 -C 10 )heteroaryl, (C 1 -C 6 )alkylene-(C 3 -C 8 )heterocycloalkyl, O—(C 1 -C 6 )alkylene-(C 5 -C 10 )heteroaryl, O—(C 1 -C 6 )alkylene-(C 3 -C 8 )heterocycloalkyl, wherein said (C 6 -C 10 )aryl or (C 5 -C 10 )heteroaryl or (C 3 -C 8 )heterocycloalkyl or (C 3 -C 8 )cycloalkyl may be substituted one to three times by a group independently selected from halogen, OH, NO 2 , CN, O—(C 1 -C 6 )alkyl, (C 1 -C 6 )alkyl, NH 2 , NH(C 1 -C 6 )alkyl, N[(C 1 -C 6 )alkyl] 2 , SO 2 CH 3 , C(O)OH, C(O)O—(C 1 -C 6 )alkyl, C(O)NH 2 , (C 1 -C 6 )alkylene-O—(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylene-O—(C 6 -C 10 )aryl, or O—(C 1 -C 6 )alkylene-(C 6 -C 10 )aryl;

or wherein (C 6 -C 10 )aryl is vicinally substituted by a O—(C 1 -C 4 )alkylene-O group whereby a 5-8-membered ring is formed together with the carbon atoms the oxygen atoms are attached to; and

wherein aryl substituents of (C 6 -C 10 )aryl, (C 5 -C 10 )heteroaryl, cycloalkyl or (C 3 -C 8 )heterocycloalkyl groups may not be further substituted by an aryl, heteroaryl, cycloalkyl or heterocycloalkyl containing group;

their stereoisomeric and/or tautomeric forms or their pharmaceutically acceptable salts.

2. A compound of formula (I) according to claim 1 , wherein R 1 is H and is characterized by the formula (II)

3. A compound of formula (I) according to claim 1 , wherein R 1 is OH and is characterized by the formula (IIIa)

or by the formula (IIIb)

4. A compound according to claim 1 , wherein R 1 is NH 2 .

5. A compound according to one of claims 1 to 4 , wherein R 3 is H, halogen, (C 1 -C 6 )alkyl, or NHR′, wherein (C 1 -C 6 )alkyl and R′ are unsubstituted or substituted.

6. A compound according to claim 1 , wherein R 3 is H.

7. A compound according to claim 1 , wherein R 4 is H, halogen, (C 1 -C 6 )alkyl or (C 1 -C 2 )alkenyl-phenyl, wherein (C 1 -C 6 )alkyl or phenyl are unsubstituted or substituted.

8. A compound according to claim 1 , wherein R 4 is H.

9. A compound according to claim 1 , wherein R 5 is H, halogen, (C 1 -C 6 )alkyl, (C 6 -C 10 )aryl, (C 3 -C 8 )cycloalkyl or (C 5 -C 10 )heteroaryl, wherein (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 6 -C 10 )aryl, or (C 5 -C 10 )heteroaryl are unsubstituted or substituted.

10. A compound according to claim 1 , wherein R 5 is H.

11. A compound according to claim 1 , wherein R 7 is H, halogen, (C 1 -C 6 )alkyl, O—(C 1 -C 6 )alkyl, or R′, wherein (C 1 -C 6 )alkyl or R′ are unsubstituted or substituted.

12. A compound according to claim 1 , wherein R 7 is hydrogen, methyl or chloro.

13. A compound according to claim 1 , wherein R 8 is H.

14. A compound according to claim 1 , wherein R 9 is

R′,

OH,

halogen,

(C 1 -C 6 )alkyl,

(C 1 -C 6 )alkylene-R′,

(C 2 -C 6 )alkenyl,

(C 1 -C 6 )alkylene-C(O)NH—R′,

(C 1 -C 6 )alkylene-C(O)NH—(C 1 -C 6 )alkyl,

COOH,

CONH 2 ,

C(O)NH—(C 1 -C 6 )alkyl,

C(O)NHR′,

C(O)—NH—(C 1 -C 6 )alkynyl,

C(O)—NH(C 1 -C 6 )alkylene-R′, or

C(O)N[(C 1 -C 6 )alkyl] 2 ;

wherein (C 1 -C 6 )alkyl, (C 1 -C 6 )alkylene or R′ are unsubstituted or substituted.

15. A compound according to claim 1 , wherein R 9 is OH, halogen, (C 1 -C 6 )alkyl, C(O)OH, C(O)NH 2 , or O—CH 3 , wherein (C 1 -C 6 )alkyl is unsubstituted or substituted.

16. A compound according to claim 1 , wherein R 9 is unsubstituted or substituted (C 1 -C 6 )alkyl.

17. A compound according to claim 1 , wherein R 10 is

(C 1 -C 6 )alkyl,

(C 1 -C 8 )heteroalkyl,

(C 3 -C 8 )cycloalkyl,

(C 3 -C 8 )heterocycloalkyl,

(C 1 -C 6 )alkylene-(C 3 -C 8 )cycloalkyl,

(C 1 -C 6 )alkylene-phenyl,

(C 1 -C 6 )alkylene-(C 5 -C 6 )heteroaryl, or

(C 1 -C 6 )alkylene-(C 5 -C 6 )heterocycloalkyl,

wherein (C 1 -C 6 )alkyl, (C 1 -C 8 )heteroalkyl, (C 3 -C 8 )cycloalkyl, (C 3 -C 8 )heterocycloalkyl, (C 1 -C 6 )alkylene, phenyl or (C 5 -C 10 )heteroaryl are unsubstituted or substituted.

18. A compound according to claim 1 , wherein R 10 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopropylmethylene, isopropyloxymethylene, tetrahydrofuranyl, tetrahydropyranyl or benzyl.

19. A compound according to claim 1 , wherein R 11 is

H,

(C 1 -C 6 )alkyl,

(C 3 -C 8 )cycloalkyl, or

(C 5 -C 6 )heteroaryl,

wherein (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, or (C 5 -C 6 )heteroaryl are unsubstituted or substituted.

20. A compound according to claim 1 , wherein R 11 is H or methyl.

21. A compound according to claim 1 , wherein R 12 is

(C 1 -C 6 )alkyl, wherein optionally one or more hydrogen are substituted by fluoro;

(C 3 -C 8 )cycloalkyl,

(C 5 -C 6 )heteroaryl, or

(C 1-6 —C 10 )aryl,

wherein (C 3 -C 8 )cycloalkyl, (C 5 -C 6 )heteroaryl or (C 6 -C 10 )aryl are unsubstituted or substituted.

22. A compound according to claim 1 , wherein R 12 is methyl, ethyl, propyl, isopropyl, cyclopropyl, trifluoromethyl, pentafluoroethyl, thiazolyl or phenyl.

23. A compound according to claim 1 , wherein R 11 and R 12 form a substituted or unsubstituted (C 3 -C 8 )cycloalkyl ring.

24. A compound according to claim 1 , wherein R 13 and R 14 are independently of each other

H,

(C 1 -C 6 )alkyl,

(C 3 -C 8 )cycloalkyl,

(C 1 -C 4 )alkylene-(C 3 -C 8 )cycloalkyl,

(C 1 -C 4 )alkylene-(C 5 -C 10 )heteroaryl,

(C 1 -C 4 )alkylene-(C 3 -C 8 )heterocycloalkyl,

C 1 -C 4 )alkylene-(C 6 -C 10 )aryl,

(C 1 -C 6 )alkylene-O—(C 1 -C 6 )alkyl,

C(O)NH—(C 1 -C 6 )alkyl, or

R 13 and R 14 , together with the N-atom to which they are attached, form a (C 3 -C 8 ) heterocycloalkyl group,

wherein (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 4 )alkylene, C 5 -C 10 )heteroaryl, (C 3 -C 8 )heterocycloalkyl, or (C 6 -C 10 )aryl are unsubstituted or substituted.

25. A compound according to claim 1 , wherein R 13 is H, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, or (C 1 -C 4 )alkylene-(C 3 -C 8 )cycloalkyl; and R 14 is

H,

(C 1 -C 6 )alkyl,

(C 3 -C 8 )cycloalkyl,

(C 1 -C 4 )alkylene-(C 3 -C 8 )cycloalkyl,

(C 1 -C 4 )alkylene-(C 5 -C 10 )heteroaryl,

(C 1 -C 4 )alkylene-(C 3 -C 8 )heterocycloalkyl,

(C 1 -C 4 )alkylene-(C 6 -C 10 )aryl,

(C 1 -C 4 )alkylene-O—(C 1 -C 6 )alkyl, or

C(O)(C 1 -C 6 )alkyl,

wherein (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 4 )alkylene, (C 5 -C 10 )heteroaryl, (C 3 -C 8 )heterocycloalkyl, or (C 6 -C 10 )aryl are unsubstituted or substituted.

26. A compound according to claim 1 , wherein

R 13 is H or (C 1 -C 6 )alkyl; and

R 14 is

H,

(C 1 -C 6 )alkyl,

(C 3 -C 8 )cycloalkyl,

(C 1 -C 4 )alkylene-(C 3 -C 8 )cycloalkyl,

(C 1 -C 4 )alkylene-(C 5 -C 10 )heteroaryl,

(C 1 -C 4 )alkylene-(C 3 -C 8 )heterocycloalkyl,

(C 1 -C 4 )alkylene-(C 6 -C 10 )aryl, or

(C 1 -C 4 )alkylene-O—(C 1 -C 6 )alkyl,

wherein (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 4 )alkylene, (C 5 -C 10 )heteroaryl, (C 3 -C 8 )heterocycloalkyl, or (C 6 -C 10 )aryl are unsubstituted or substituted.

27. A compound according to claim 1 , wherein

R 13 is H, (C 1 -C 6 )alkyl and

R 14 is H, (C 1 -C 6 )alkyl or (C 3 -C 8 )cycloalkyl,

wherein (C 1 -C 6 )alkyl or (C 3 -C 8 )cycloalkyl are unsubstituted or substituted.

28. A compound according to claim 1 , wherein R 13 and R 14 are H.

29. A compound according to claim 1 , wherein R 6 is absent or the bicyclic ring system or adamantane formed with R 6 is selected from

which are unsubstituted or optionally substituted by R 9 .

30. A compound according to claim 1 , wherein R 6 is absent.

31. A compound according to claim 1 , wherein m is 2 and s is 2.

32. A compound according to claim 1 , wherein m is 3 and s is 1.

33. A compound according to claim 1 , wherein n is 0, 1, or 2.

34. A compound according to claim 1 , wherein n is 0.

35. A compound according to claim 1 , wherein r is 1.

36. A compound according to claim 1 , wherein L is S(CH 2 )p, S(O)(CH 2 )p, or SO 2 (CH 2 )p.

37. A compound according to claim 1 , wherein L is NH(CH 2 )p or N(C 1 -C 6 )alkyl)-(CH 2 )p.

38. A compound according to claim 1 , wherein L is O(CH 2 )p.

39. A compound according to claim 1 , wherein p is 0.

40. A compound according to claim 1 selected from the group consisting of

6-[4-(1-Amino-propyl)-4-(tetrahydro-pyran-4-yl)-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-ethyl)-4-ethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-propyl)-4-propyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(Amino-cyclopropyl-methyl)-4-propyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-propyl)-4-isopropyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-ethyl)-4-cyclopropylmethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-propyl)-4-cyclopropylmethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-butyl)-4-cyclopropylmethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(Amino-cyclopropyl-methyl)-4-cyclopropylmethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-2-methyl-propyl)-4-cyclopropylmethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-propyl)-4-isopropoxymethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-ethyl)-4-cyclobutyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-propyl)-4-cyclobutyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-propyl)-4-cyclopentyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(Amino-phenyl-methyl)-4-cyclopentyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-propyl)-4-methyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-propyl)-4-isobutyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-propyl)-4-benzyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one

6-[4-(1-Amino-propyl)-4-ethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-butyl)-4-isopropyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-butyl)-4-ethyl-cyclohexyloxy]-7-methyl-2H-isoquinolin-1-one,

6-[4-(1-Amino-ethyl)-4-ethyl-cyclohexyloxy]-7-methyl-2H-isoquinolin-1-one,

6-[4-(1-Amino-propyl)-4-butyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-propyl)-4-butyl-cyclohexyloxy]-4-benzyl-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-2,2,2-trifluoro-ethyl)-4-cyclopropylmethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-2,2,2-trifluoro-ethyl)-4-isopropyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-2,2,3,3,3-pentafluoro-propyl)-4-isopropyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(Amino-thiazol-2-yl-methyl)-4-isopropyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one, and

6-[4-(Amino-thiazol-5-yl-methyl)-4-isopropyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one, their stereoisomeric and/or tautomeric forms or their pharmaceutically acceptable salts thereof.

41. A compound according to claim 1 selected from the group consisting of

cis-6-[4-(1-amino-propyl)-4-(tetrahydropyran-4-yl)-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-propyl)-4-ethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-butyl)-4-isopropyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-butyl)-4-ethyl-cyclohexyloxy]-7-methyl-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-ethyl)-4-ethyl-cyclohexyloxy]-7-methyl-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-propyl)-4-butyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one, and

cis-6-[4-(1-Amino-propyl)-4-butyl-cyclohexyloxy]-4-benzyl-7-chloro-2H-isoquinolin-1-one,

their stereoisomeric or tautomeric forms and/or pharmaceutically acceptable salts thereof.

42. A compound according to claim 1 selected from the group consisting of

cis-6-[4-((S)-1-Amino-propyl)-4-methyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-((R)-1-Amino-propyl)-4-methyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-((S)-1-Amino-propyl)-4-(tetrahydro-pyran-4-yl)-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-((R)-1-Amino-propyl)-4-(tetrahydro-pyran-4-yl)-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-((R)-1-Amino-propyl)-4-ethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-((S)-1-Amino-propyl)-4-ethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-((S)-Amino-cyclopropyl-methyl)-4-cyclopropylmethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one, and

cis-6-[4-((R)-Amino-cyclopropyl-methyl)-4-cyclopropylmethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

their tautomeric forms or pharmaceutically acceptable salts thereof.

43. A compound according to claim 1 selected from the group consisting of

cis-6-[4-(1-Amino-ethyl)-4-ethyl-cyclohexyloxy]-7-methyl-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-propyl)-4-ethyl-cyclohexyloxy]-7-fluoro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-propyl)-4-ethyl-cyclohexyloxy]-7-fluoro-5-methyl-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-propyl)-4-ethyl-cyclohexyloxy]-7-methyl-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-propyl)-4-ethyl-cyclohexyloxy]-5,7-dimethyl-2H-isoquinolin-1-one,

cis-6-[-4-(1-Amino-propyl)-4-methoxy-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

trans-6-[4-(1-Amino-propyl)-4-methoxy-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-propyl)-4-ethoxy-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(Amino-phenyl-methyl)-4-methyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-butyl)-4-methyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(Amino-phenyl-methyl)-4-cyclopropylmethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-3-methyl-butyl)-4-cyclopropylmethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-2-methyl-propyl)-4-cyclohexyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-propyl)-4-(4,4,4-trifluoro-butyl)-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-propyl)-4-(tetrahydro-pyran-4-ylmethyl)-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(Amino-cyclopropyl-methyl)-4-(tetrahydro-pyran-4-ylmethyl)-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(Amino-cyclopropyl-methyl)-4-methyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(Amino-cyclopropyl-methyl)-4-ethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-propyl)-4-ethoxymethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-ethyl)-4-cyclopropyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(Amino-cyclopropyl-methyl)-4-(4,4,4-trifluoro-butyl)-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-propyl)-4-cyclopropyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(Amino-cyclopropyl-methyl)-4-cyclopropyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-propyl)-4-(tetrahydro-thiopyran-4-yl)-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-ethyl)-4-propyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-ethyl)-4-ethyl-cyclohexyloxy]-7-fluoro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-ethyl)-4-ethyl-cyclohexyloxy]-7-fluoro-5-methyl-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-ethyl)-4-ethyl-cyclohexyloxy]-4-benzyl-7-chloro-2H-isoquinolin-1-one,

cis-7-Chloro-6-{4-[1-(cyclopropylmethyl-amino)-propyl]-4-ethyl-cyclohexyloxy}-2H-isoquinolin-1-one,

cis-6-[4-(1-Benzylamino-propyl)-4-ethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-7-Chloro-6-[4-ethyl-4-(1-isobutylamino-propyl)-cyclohexyloxy]-2H-isoquinolin-1-one,

cis-6-[4-(1-Butylamino-propyl)-4-ethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-Amino-2-methyl-propyl)-4-isopropyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-propyl)-4-isopropyl-cyclohexyloxy]-7-chloro-4-fluoro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-propyl)-4-ethyl-cyclohexyloxy]-7-chloro-4-fluoro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-propyl)-4-ethyl-cyclohexyloxy]-4-bromo-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(1-Amino-propyl)-4-ethyl-cyclohexyloxy]-7-chloro-1-oxo-1,2-dihydro-isoquinoline-4-carbonitrile,

cis-6-[4-(1-Amino-propyl)-4-isopropyl-cyclohexyloxy]-4-bromo-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(1-amino-2-fluoro-ethyl)-4-ethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

trans-6-[4-(1-amino-2-fluoro-ethyl)-4-ethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[4-(1-amino-3-methoxy-propyl)-4-ethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

cis-6-[4-(1-amino-propyl)-4-(1,1-dioxo-tetrahydrothiopyran-4-yl)-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

6-[3-(1-Amino-propyl)-3-propyl-cyclopentoxy]-7-chloro-2H-isoquinolin-1-one, and

6-[4-(1-Amino-propyl)-4-trifluoromethyl-cyclohexyloxy]-7-chloro-2H-isoquinolin-1-one,

their stereoisomeric and/or tautomeric forms or pharmaceutically acceptable salts thereof.

44. A compound according to claim 1 selected from the group consisting of

cis1-[4-(5,7-Dimethyl-isoquinolin-6-yloxy)-1-ethyl-cyclohexyl]-propylamine,

cis-1-[1-Ethyl-4-(7-fluoro-isoquinolin-6-yloxy)-cyclohexyl]-propylamine,

cis-1-[1-Ethyl-4-(7-methyl-isoquinolin-6-yloxy)-cyclohexyl]-propylamine,

cis-1-[1-Ethyl-4-(7-fluoro-5-methyl-isoquinolin-6-yloxy)-cyclohexyl]-propylamine,

cis-1-[1-Ethyl-4-(7-fluoro-5-methyl-isoquinolin-6-yloxy)-cyclohexyl]-ethylamine,

cis-1-[4-(7-Bromo-isoquinolin-6-yloxy)-1-ethyl-cyclohexyl]-ethylamine,

cis-1-[4-(7-Methyl-isoquinolin-6-yloxy)-1-ethyl-cyclohexyl]-ethylamine,

cis-1-[4-(5-Chloro-isoquinolin-6-yloxy)-1-ethyl-cyclohexyl]-ethylamine,

cis-6-[4-(1-Amino-ethyl)-4-propyl-cyclohexyloxy]-7-chloro-isoquinolin-1-ylamine, and

[4-(1-Amino-propyl)-4-methyl-cyclohexyl]-isoquinolin-6-yl-amine,

and their stereoisomeric and/or tautomeric forms or pharmaceutically acceptable salts thereof.

45. A compound of formula (I) or its pharmaceutically acceptable salt according to claim 1 for use as a medicament.

46. A pharmaceutical composition comprising an effective amount of at least one compound of formula (I) or pharmacologically acceptable salt thereof according to claim 1 , pharmaceutically tolerated excipients and carriers and, where appropriate, further additives and/or other active ingredients.